ストックスクリーナーアプリを入手
2.19
8.96%
0.18
アフターアワーズ：
2.17
-0.02
-0.91%
前日終値:
$2.01
開ける：
$2.03
24時間の取引高:
1.88M
Relative Volume:
1.37
時価総額：
$126.58M
収益：
-
当期純損益:
$-44.80M
株価収益率:
-2.92
EPS:
-0.75
ネットキャッシュフロー:
$-30.67M
1週間 パフォーマンス:
+15.87%
1か月 パフォーマンス:
-65.29%
6か月 パフォーマンス:
-60.54%
1年 パフォーマンス:
-44.84%
1日の値動き範囲:
$2.03
$2.225
1週間の範囲:
$1.79
$2.36
52週間の値動き範囲:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
名前
Aldeyra Therapeutics Inc
セクター
電話
781-761-4904
住所
131 HARTWELL AVENUE, LEXINGTON, MA
ALDX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
2.19 | 126.58M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-03 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-04-02 | 再開されました | H.C. Wainwright | Buy |
| 2022-04-27 | 再開されました | H.C. Wainwright | Buy |
| 2021-02-08 | 開始されました | H.C. Wainwright | Buy |
| 2020-12-16 | 開始されました | Berenberg | Buy |
| 2020-10-30 | 開始されました | Jefferies | Buy |
| 2020-10-16 | 開始されました | BTIG Research | Buy |
| 2020-09-22 | 開始されました | Alliance Global Partners | Buy |
| 2020-05-12 | 開始されました | Oppenheimer | Outperform |
| 2018-12-04 | 開始されました | Citigroup | Buy |
| 2018-09-26 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 開始されました | Janney | Buy |
| 2018-01-26 | 開始されました | Seaport Global Securities | Buy |
| 2016-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2016-07-01 | 開始されました | Stifel | Buy |
| 2015-07-01 | 開始されました | Canaccord Genuity | Buy |
| 2015-03-25 | 開始されました | Chardan Capital Markets | Buy |
| 2015-03-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2014-11-18 | 開始されました | H.C. Wainwright | Buy |
| 2014-06-19 | 開始されました | Aegis Capital | Buy |
すべてを表示
Aldeyra Therapeutics Inc (ALDX) 最新ニュース
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA’s Reproxalap Complete Response Letter – Hagens Berman - GlobeNewswire Inc.
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra - Bluefield Daily Telegraph
ALDX INVESTOR INVESTIGATION: Aldeyra Therapeutics, Inc. - GlobeNewswire
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors - citybiz
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors | ALDX Stock News - GuruFocus
Research Analysts Set Expectations for ALDX Q1 Earnings - Defense World
What is Leerink Partnrs’ Estimate for ALDX Q2 Earnings? - Defense World
Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - markets.businessinsider.com
American Century Companies Inc. Reduces Stock Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra (ALDX) Pre-Earnings Options Activity Signals Potential P - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
ALDX STOCK REMINDER: The Aldeyra Therapeutics, Inc. - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation - markets.businessinsider.com
Aldeyra Therapeutics (NASDAQ:ALDX) Price Target Cut to $9.00 by Analysts at BTIG Research - MarketBeat
ALDX STOCK NOTIFICATION: Did Aldeyra Therapeutics, Inc. - GlobeNewswire
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After - GlobeNewswire
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Hay Fever Conjunctivitis Therapeutics Market Size in 7MM - openPR.com
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response LetterHagens Berman - The Malaysian Reserve
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on - Bluefield Daily Telegraph
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect - markets.businessinsider.com
ALDX CLASS NOTICE: An Investigation has been Initiated on - GlobeNewswire
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA’s Reproxalap Complete Response Letter – Hagens Berman - TradingView
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
ALDX SECURITIES NOTIFICATION: Aldeyra Therapeutics, Inc. Investors that Suffered Losses are Notified to Contact BFA Law - Newsfile
Aldeyra therapeutics sees $4.83 million stock sale by major shareholder - Investing.com South Africa
After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (NASDAQ:ALDX) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Aldeyra’s Dry Eye Drug Gets Another Rejection from the FDA - Contract Pharma
ALDX SECURITIES REPORT: Aldeyra Therapeutics, Inc. - GlobeNewswire
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): When Will It Breakeven? - simplywall.st
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Investors to Inquire about Securities Investigation - markets.businessinsider.com
ALDX SECURITIES NOTICE: Aldeyra Therapeutics, Inc. Investors with Losses are Notified to Contact BFA Law as they may have been Affected by Securities Violations - Newsfile
ALDX SECURITIES ALERT: Aldeyra Therapeutics, Inc. Investors - GlobeNewswire
Aldeyra Therapeutics’ (ALDX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
INVESTOR ALERT: Investigation of Aldeyra Therapeutics, Inc. (ALDX) Announced by Holzer & Holzer, LLC - GlobeNewswire
Kirby McInerney LLP Announces Investigation of Possible - GlobeNewswire
Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays Optimistic - MSN
Aldeyra Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsADLX - ACCESS Newswire
Aldeyra Expects Mid-2025 Refiling Of Reproxalap After Second CRL - insights.citeline.com
Laidlaw maintains Buy on Aldeyra, sees upside despite FDA setback - Investing.com India
ALDX ALERT: BFA Law Informs Aldeyra Therapeutics, Inc. Investors to Contact the Firm about its Securities Investigation - Newsfile
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Aldeyra vows to go ahead after fresh reproxalap setback - The Pharma Letter
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - markets.businessinsider.com
Aldeyra Therapeutics Inc (ALDX) 財務データ
収益
当期純利益
現金流量
EPS
Aldeyra Therapeutics Inc (ALDX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Machatha Stephen | Chief Development Officer |
Aug 12 '24 |
Sale |
4.74 |
16,041 |
75,975 |
236,771 |
| Greenberg Bruce | See Remarks |
Aug 12 '24 |
Sale |
4.74 |
10,834 |
51,313 |
126,382 |
2.51%
大文字化:
|
ボリューム (24 時間):